Caxton Associates (UK)
NEO icon

Caxton Associates (UK)’s NeoGenomics NEO Stock Holding History

Caxton Associates (UK)’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$875K Buy
+47,676
New +$787K 0.02% 358

Other funds holding NEO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Caxton Associates (UK)'s NEO Position: Q3 2026 in Review

Caxton Associates (UK) opened a new position in NeoGenomics (NEO) in Q3 2026: 47,676 shares worth $875K. The stake represents 0.02% of the portfolio and ranks #358 among its holdings.

231 funds tracked by Wall St. Rank hold NEO as of Q3 2026.

  • Caxton Associates (UK) held 47,676 shares of NeoGenomics worth $875K as of Q3 2026.
  • NeoGenomics was a new Caxton Associates (UK) position in Q3 2026.
  • NeoGenomics made up 0.02% of Caxton Associates (UK)'s portfolio in Q3 2026, its #358 holding.
  • 231 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2026.

Based on Caxton Associates (UK)'s 13F filing for Q3 2026, filed 13 Nov 2026.